Specialty
Our proven strategies including step therapy, Specialty Guideline Management, and cross-benefit management can help clients better manage costs for the growing number of IBD... More
Feature
“Drug Pipeline”
18 result(s)
Drug Pipeline
Over the past dozen years, several new treatments have come to market with the first oral preventive expected to be approved in December. Targeted management to help balance... More
Feature
Drug Pipeline
After many years of failure, there is hope for potential treatments that could slow disease progression for those with Alzheimer's Disease. If approved, Biogen's... More
Feature
Drug Pipeline
New drugs likely to offer patients more options. Key consideration for payors will be effectively balancing high — and rising — price tags with appropriate access. More
Feature
Cost Management
Gene therapies have the potential to relieve tremendous suffering for patients with genetic disorders and together we can find ways to ensure these treatments are accessible for... More
White Paper
Drug Pipeline
CVS Health provides an early look at some key Breakthrough Therapies expected to be reviewed by the FDA in 2020 as well as the associated cost implications and expected approval... More
Feature
Drug Pipeline
New drugs to treat migraine are approaching approval and could bring relief for many patients, but they portend higher costs. Ongoing monitoring and appropriate utilization... More
Feature
Drug Pipeline
Biosimilars are a critical tool PBMs can use to help increase market competition and lower costs – we made changes to our template formularies for categories that now have... More
Feature
Drug Pipeline
An overview of recently approved therapies, anticipated approvals in the year to come, and strategies to help manage the pipeline More
Feature
Drug Pipeline
Peanut allergy is the most common of childhood food allergies — and getting more common. Research presented at the annual meeting of the American College of Allergy, Asthma and... More
Feature